Monitor for potential share sales by the selling stockholders, which could create downward pressure on the stock price. The $25 million in funding provides runway for clinical development, but watch for future dilutive offerings if additional capital is needed.
Price Chart
Executive Summary
Opus Genetics filed an S-3 shelf registration to register 7,374,632 shares of common stock for resale by selling stockholders, representing shares issuable upon conversion of Series B Preferred Stock issued in a private placement. The company received $25 million in net proceeds from the private placement, which will be used for clinical programs and general corporate purposes. The registration satisfies a contractual obligation and does not raise new capital for the company.
Key Facts
- S-3 filing registers 7,374,632 shares for resale by selling stockholders
- Shares are issuable upon conversion of Series B Preferred Stock from a private placement
- Company received $25 million in net proceeds from the private placement
- Proceeds will be used to advance gene therapy clinical programs and for working capital
- Company will not receive any proceeds from the resale of shares by selling stockholders
- Registration satisfies a contractual obligation under a registration rights agreement
Financial Impact
The registration itself has no direct financial impact as the company won't receive proceeds from share resales. However, the $25 million from the private placement provides funding for clinical programs.
Risk Factors
- Potential share price pressure from resale of registered shares
- Future dilution if additional capital is raised through equity offerings
- Clinical trial risks for gene therapy programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-009408 |
| Document: ny20067725x1_ex107.htm | 0001140361-26-009408 |
| Document: ny20067725x1_ex23-1.htm | 0001140361-26-009408 |
| Document: 0001140361-26-009408-index-headers.html | 0001140361-26-009408 |
| Document: 0001140361-26-009408-index.html | 0001140361-26-009408 |
| Document: 0001140361-26-009408.txt | 0001140361-26-009408 |
| CONTEXT: 10-Q (2025-11-12) | 0001140361-25-041547 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.32 (−5.68%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.32 (−13.09%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.32 (−13.54%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.32 (−35.66%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.32 (−45.03%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.32 (−42.06%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.32 (−25.39%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.32 (−10.75%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.32 (+13.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers